What DyDo Pharma does

DyDo Pharma Co., Ltd. (ダイドーファーマ株式会社) is a privately held Japanese specialty pharmaceutical company founded in March 2019 in Osaka as a wholly-owned subsidiary of DyDo Group Holdings Co., Ltd. The company is focused exclusively on developing and commercializing treatments for rare diseases, with its single therapeutic focus being Lambert-Eaton myasthenic syndrome (LEMS), an ultra-rare autoimmune neuromuscular disorder with a reported Japanese prevalence of 0.27 per 100,000.

The company's core product is FIRDAPSE® Tablets 10mg, an oral formulation of amifampridine phosphate — a voltage-gated potassium (K+) channel blocker that extends depolarization at the presynaptic terminal of the neuromuscular junction, increasing acetylcholine release and improving muscle weakness in LEMS patients. The drug was in-licensed from Catalyst Pharmaceuticals under an exclusive Japanese development and commercialization agreement signed in June 2021, validated through a Japanese Phase III trial (LMS-005), and received Japanese manufacturing and marketing approval on September 24, 2024. It was commercially launched in Japan on January 21, 2025, as the first oral treatment approved in Japan for LEMS, and holds Japanese orphan (R3) drug designation (#515, May 2021).

DyDo Pharma's business model is a classic specialty/orphan pharmaceutical model: it sells a single, NHI-priced prescription drug through licensed pharmaceutical wholesalers to hospitals and specialist clinics, primarily targeting neurologists and neuroimmunologists. The company supports uptake through medical representative field activities, sponsorship of Japanese neurology and neuroimmunology societies, and dedicated disease-information websites for healthcare professionals and patients. Revenue is generated from prescription drug sales at NHI-regulated prices, and the company has built supporting infrastructure including a dedicated logistics center opened in October 2024.

Name

DyDo Pharma

Legal name

ダイドーファーマ株式会社

Website

https://dydopharma.co.jp

Company type

Private

Founded year

2019

Operating status

Operating

Short description

DyDo Pharma is a Japanese specialty pharmaceutical subsidiary of DyDo Group Holdings that develops and commercializes FIRDAPSE® Tablets 10mg, the first oral treatment approved in Japan for the rare autoimmune neuromuscular disorder Lambert-Eaton myasthenic syndrome (LEMS).

Ownership category

akta.pro rank

Headquarters

HQ city

Osaka

HQ country

Japan

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Distribution channels1 record

Marketing channels4 records

Core offering

DyDo Pharma develops, manufactures, and commercializes FIRDAPSE® Tablets 10mg (amifampridine phosphate), Japan's first approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS). The drug is a voltage-gated potassium channel blocker that improves neuromuscular transmission by extending depolarization at the presynaptic terminal and promoting acetylcholine release. The company also supports prescribers and patients via dedicated disease-information websites.

Product overview

DyDo Pharma is a pharmaceutical company focused on developing and commercializing treatments for rare diseases, specifically Lambert-Eaton myasthenic syndrome (LEMS). The company's main product is FIRDAPSE® Tablets 10mg (amifampridine phosphate), the first oral treatment approved in Japan for LEMS. The company operates dedicated disease information platforms for both medical professionals and patients/general public to support awareness and proper diagnosis of LEMS.

Differentiator

Problem solved

Functional benefit

Brands

• FIRDAPSE® Tablets 10mg (ファダプス®錠10mg): Lambert-Eaton myasthenic syndrome (LEMS) treatment drug containing amifampridine phosphate (3,4-diaminopyridine). It is Japan's first oral treatment for LEMS.

Products and services

• FIRDAPSE® Tablets 10mg (ファダプス®錠10mg) FIRDAPSE® Tablets 10mg is an oral prescription pharmaceutical containing amifampridine phosphate (10mg per tablet) used for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adult patients. It is a voltage-gated potassium channel blocker that extends the depolarization time at the presynaptic terminal of the neuromuscular junction, promoting acetylcholine release to enhance neuromuscular transmission and improve muscle weakness. It is Japan's first approved oral treatment for LEMS and is prescribed by neurologists.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Catalyst Pharmaceuticals (Catalyst Biosciences at time of original deal)coreOEM/ Whitelabel/ Licensing Partner · 28 June 2021DyDo Pharma acquired exclusive rights from Catalyst Pharmaceuticals to develop and commercialize amifampridine phosphate (FIRDAPSE®) for the Japanese market. The licensing agreement covers LEMS indication. The drug was subsequently developed through Japanese Phase III clinical trials (LMS-005), received approval in Japan in September 2024, and was commercially launched in January 2025.

Recent moves7 records

Expansion highlights4 records

Emerging players

• argenx: A Belgium-based biotech focused on severe autoimmune diseases including myasthenia gravis (a related neuromuscular autoimmune disorder). Comparable in neuromuscular autoimmune disease focus and orphan-drug commercial model.

Broad incumbents

• BioMarin Pharmaceutical: A larger US rare-disease biopharma with a portfolio of orphan drugs for small patient populations. Comparable in business model of focusing on rare diseases with premium pricing and orphan drug protections.
• Ultragenyx Pharmaceutical: A commercial-stage rare-disease biotech developing and commercializing therapies for rare and ultra-rare genetic diseases. Comparable in targeting small patient populations via orphan-drug commercialization.
• Takeda Pharmaceutical (Rare Diseases): Japan's largest pharma company with a substantial rare-disease franchise (post-Shire acquisition). Comparable as a Japan-based rare-disease commercial player, though at vastly greater scale.
• UCB (Rare Disease portfolio): UCB develops and markets therapies for rare neurological and immunological conditions including myasthenia gravis. Comparable as a large pharma with neuromuscular rare-disease commercial operations.
• Sanofi Genzyme (Rare Disease): Sanofi's Genzyme unit is a global leader in rare diseases (including rare neurological disorders). Comparable as an established rare-disease commercial operation with orphan-drug expertise and global reach.
• Alexion / AstraZeneca Rare Disease: Alexion pioneered the rare-disease commercial model with Soliris/Ultomiris for rare complement-mediated disorders. Highly comparable as the gold-standard rare-disease commercial organization.

Direct peers

• Catalyst Pharmaceuticals: Catalyst Pharmaceuticals developed and commercializes FIRDAPSE® (amifampridine) for LEMS in the US — DyDo Pharma's licensor and the originator of the asset DyDo is commercializing in Japan, making it the most directly comparable commercial peer.
• Recordati Rare Diseases: Recordati's rare disease business commercializes treatments for rare conditions including LEMS in Europe. Closely comparable to DyDo Pharma as a rare-disease-focused commercial entity with global reach.

Regional players

• Japan Tobacco Inc. (Pharmaceutical Division): Japan Tobacco's pharmaceutical division focuses on rare and intractable diseases, including products overlapping with neurology/autoimmune indications. Comparable as a Japanese pharma with a rare-disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DyDo Pharma